New treatments in atopic dermatitis update.

Area of Science:

• Dermatology and Immunology
• Pharmacology and Therapeutics

Background:

• Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant impact on quality of life.
• Existing treatments for AD have limitations, necessitating the development of novel therapeutic strategies.

Purpose of the Study:

• To review the efficacy and safety of emerging topical and systemic therapies for atopic dermatitis in pediatric and adult populations.
• To highlight recent advancements and future directions in AD treatment.

Main Methods:

• Comprehensive literature search of peer-reviewed publications (PubMed), meeting abstracts, ClinicalTrials.gov, and industry press releases.
• Evaluation of novel and emerging therapies, including nonsteroidal topicals, topical Janus kinase (JAK) inhibitors, biologics, and oral JAK inhibitors.
• Assessment of therapies targeting specific pathways like IL-4/IL-13, IL-31, and OX40/OX40L.

Main Results:

• Several new agents have received FDA approval, expanding therapeutic options for AD.
• Approved nonsteroidal topical treatments include roflumilast and tapinarof.
• Biologics targeting IL-4/IL-13 (dupilumab, tralokinumab, lebrikizumab) and IL-31 receptor (nemolizumab) are available for various age groups.
• Oral JAK inhibitors (upadacitinib, abrocitinib) are approved for patients aged 12 and older in the US.

Conclusions:

• Innovations in AD therapy signify a move towards personalized treatment approaches.
• Investigational therapies like bacteriotherapy and agents targeting OX40/OX40L show promise.
• Continued research is crucial for assessing long-term safety, efficacy, and optimizing patient outcomes.